Format

Send to

Choose Destination
JAMA Otolaryngol Head Neck Surg. 2013 Feb;139(2):173-82. doi: 10.1001/jamaoto.2013.1360.

Oncolytic vaccinia virus therapy of salivary gland carcinoma.

Author information

1
Departments of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Abstract

OBJECTIVE:

To examine the therapeutic effects of an attenuated, replication-competent vaccinia virus (GLV-1h68) against a panel of 5 human salivary gland carcinoma cell lines.

DESIGN:

The susceptibility of 5 salivary gland carcinoma cell lines to infection and oncolysis by GLV-1h68 was assessed in vitro and in vivo.

RESULTS:

All 5 cell lines were susceptible to viral infection, transgene expression, and cytotoxic reactions. Three cell lines were exquisitely sensitive to infection by very low doses of GLV-1h68. Orthotopic parotid tumors exhibited more aggressive behavior compared with flank tumors. A single intratumoral injection of GLV-1h68 induced significant tumor regression without observed toxic effects in flank and parotid tumor models; controls demonstrated rapid tumor progression.

CONCLUSION:

These promising results demonstrate significant oncolytic activity by an attenuated vaccinia virus for infecting and lysing salivary gland carcinomas, supporting future clinical trials.

PMID:
23429949
PMCID:
PMC4413455
DOI:
10.1001/jamaoto.2013.1360
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center